December 16, 2013
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) is revving up its lobbying campaigns to garner political support for the proposed institutionalization of the premium for new drug development. FPMAJ Chairman Haruo Naito touted the institutionalization, along with other...read more